Aminopyrazinamides: Novel and specific GyrB inhibitors that kill replicating and nonreplicating mycobacterium tuberculosis

ACS Chemical Biology

Volumn 8, Issue 3, 2013, Pages 519-523

  Shirude, Pravin S ^a   Madhavapeddi, Prashanti ^a   Tucker, Julie A ^a   Murugan, Kannan ^a   Patil, Vikas ^a   Basavarajappa, Halesha ^a   Raichurkar, Anandkumar V ^a   Humnabadkar, Vaishali ^a   Hussein, Syeed ^a   Sharma, Sreevalli ^a   Ramya, V K ^a   Narayan, Chandan B ^a   Balganesh, Tanjore S ^a   Sambandamurthy, Vasan K ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE; TUBERCULOSTATIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; PYRAZINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG SELECTIVITY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; METABOLISM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING;

DNA GYRASE; DOSE-RESPONSE RELATIONSHIP, DRUG; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

EID: 84875146874     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb300510w     Document Type: Article

References (13)

1. WHO TB report. http://www.who.int/mediacentre/news/releases/2011/tb- 20111011/en/index.html.
2. Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., Soolingen, D., Jensen, P., and Bayona, J. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis Lancet 375, 1830-1843
3. Lienhardt, C., Glaziou, P., Uplekar, M., Lönnroth, K., Getahun, H., and Raviglione, M. (2012) Global tuberculosis control: lessons learnt and future prospects Nat. Rev. Microbiol. 10, 407-416
4. Mitchison, D. A. (2004) The search for new sterilizing anti-tuberculosis drugs Front. Biosci. 9, 1059-1072
5. Koul, A., Arnoult, E., Lounis, N., Guillemont, J., and Andries, K. (2011) The challenge of new drug discovery for tuberculosis Nature 469, 483-490
6. Ferrero, L., Cameron, B., Manse, B., Lagneaux, D., Crouzet, J., Famechon, A., and Blanche, F. (1994) Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones Mol. Microbiol. 13, 641-653
7. Mdluli, K. and Ma, Z. (2007) Mycobacterium tuberculosis DNA gyrase as a target for drug discovery Infect. Dis. Drug Targets 7, 159-168
8. Miyamoto, T., Matsumoto, J., Chiba, K., Egawa, H., Shibamori, K., Minamida, A., Nishimura, Y., Okada, H., Kataoka, M., Fujitla, M., Hirose, T., and Nakano, J. (1990) Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency J. Med. Chem. 33, 1645-1656
9. Maxwell, A. (1993) The interaction between coumarin drugs and DNA gyrase Mol. Microbiol. 9, 681-686
10. Chopra, S., Matsuyama, K., Tran, T., Malerich, J. P., Wan, B., Franzblau, S. G., Lun, S., Guo, H., Maiga, M. C., Bishai, W. R., and Madrid, P. B. (2012) Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis J. Antimicrob. Chemother. 67, 415-421
11. Charifson, P. S., Grillot, A., Grossman, T. H., Parsons, J. D., Badia, M., Bellon, S., Deininger, D. D., Drumm, J. E., Gross, C. H., LeTiran, A., Liao, Y., Mani, N., Nicolau, D. P., Perola, E., Ronkin, S., Shannon, D., Swenson, L. L., Tang, Q., Tessier, P. R., Tian, S., Trudeau, M., Wang, T., Wei, Y., Zhang, H., and Stamos, D. (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships J. Med. Chem. 51, 5243-5263
12. Bellon, S., Parsons, J. D., Wei, Y., Hayakawa, K., Swenson, L. L., Charifson, P. S., Lippke, J. A., Aldape, R., and Gross, C. H. (2004) Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 Kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase Antimicrob. Agents Chemother. 48, 1856-1864
13. Grossman, T. H., Bartels, D. J., Mullin, S., Gross, C. H., Parsons, J. D., Liao, Y., Grillot, A., Stamos, D., Olson, E. R., Charifson, P. S., and Mani, N. (2007) Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds Antimicrob. Agents Chemother. 51, 657-666